Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
Site Search
The Cystic Fibrosis Foundation has followed the health care reform discussion closely. While the Foundation has not taken a position on any particular health reform bill, we have consistently and aggressively encouraged officials to include specific reforms that are important for the treatment of cystic fibrosis.
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Ever wondered what it takes for a potential cystic fibrosis drug to become approved by the U.S. Food and Drug Administration? Here's an explanation of the four phases of clinical research.
On March 20, the Cystic Fibrosis Foundation and 86 other organizations called on Congress to protect Medicaid, a critical source of coverage for people in the cystic fibrosis community.
Earlier this month, we learned that the new CF drug Orkambi was approved by the FDA. This was such an exciting, memorable and emotional day for everyone in the CF community. We heard from many who were thrilled about the potential for this drug to help people with CF and also heard from those who would not benefit from this breakthrough. Following are some reactions from those this impacts the most: people with CF and their loved ones.
This week, House committees released legislation to repeal and replace the Affordable Care Act. The Cystic Fibrosis Foundation issued a statement consistent with our ongoing work to promote policies to help ensure that people with cystic fibrosis have access to high-quality, specialized care and adequate affordable insurance.